Home
Learn More
Release Features
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
May 17, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
 
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
Close Move
All Press Releases for January 18, 2008 Subscribe to this News Feed      
 

Innovative Cold Sore Treatment Device Virulite Comes to US

Successful in the UK, Device Reduces Healing Time by up to 50%

COSTA MESA, Calif. (Business Wire EON/PRWEB ) January 18, 2008 -- Virulite, LLC, a medical device manufacturer dedicated to developing the market for an innovative new treatment for cold sores, today announced that it has retained Compass Point Capital, Inc. and Murphy Business and Financial Corporation as its mergers and acquisitions advisors.

Virulite, LLC has validated the US market for the Virulite device by successfully completing clinical trials and is presently in the process of obtaining FDA clearance. The Virulite product is successful in the UK and is both approved by the British National Health Service and CE marked.

The Virulite product, (patents granted and pending), is a portable, hand held device that uses an invisible, non-thermal band of near-infrared light. Virulite was developed in the UK after ten years of research and development, and has been medically proven in independent clinical trials to reduce the healing time of cold cores by up to one half.

The company completed a US market test of the product through Walgreens online distribution channel, where Virulite outsold all competing cold sore remedies, including the current market leader, the topical cream Abreva by GlaxoSmithKline (GSK). In addition, Virulite received numerous customer testimonials from users who experienced astonishing results. Virulite, LLC recognizes the product requires a home with an established pharmaceutical, health product or medical device company in order to effectively penetrate the estimated $4 billion cold sore remedy market, and is actively seeking suitors.

About Virulite, LLC

Virulite LLC is focused on developing consumer markets using the Virulite 1072 nanometer technology. While the cold sore treatment is proven, the technology also has shown anecdotal success in treating genital herpes, bacterial infections and warts (clinical trials are underway for the latter two). For more information, visit http://www.virulite.com

About Compass Point Capital, Inc. and Murphy Business and Financial Corporation

Compass Point is a leading west coast mergers and acquisition firm specializing in middle market companies and will be working with Murphy Business, one of the largest business sales organizations with offices nationwide. For more information, visit http://www.compasspointcapital.com and http://www.murphybusiness.com

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/SGFsZi1Db3VwLUNyYXMtSG9yci1Mb3ZlLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web



OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareIt

Share The News

Submit this press release easily to any of these major bookmarking and social media sites.

CONTACT INFORMATION

Murphy Business and Finance
Randy Malmud, 310-285-1760
Fax: 310-694-9079
R.malmud@murphybusiness.com

ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files by creating a Smart News Release at Business Wire.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright